Help | Sitemap | Archive | Advanced Search | Mirror in USA   
  CHINA
  BUSINESS
  OPINION
  WORLD
  SCI-EDU
  SPORTS
  LIFE
  WAP SERVICE
  FEATURES
  PHOTO GALLERY

Message Board
Feedback
Voice of Readers
China Quiz
 China At a Glance
 Constitution of the PRC
 State Organs of the PRC
 CPC and State Leaders
 Chinese President Jiang Zemin
 White Papers of Chinese Government
 Selected Works of Deng Xiaoping
 English Websites in China
Help
About Us
SiteMap
Employment

U.S. Mirror
Japan Mirror
Tech-Net Mirror
Edu-Net Mirror
 
Monday, March 12, 2001, updated at 21:19(GMT+8)
China  

NPC Deputy Proposes Law on Genetically-Engineered Medicines

A law on the management of genetically-engineered medicines needs to be enacted to promote and systematically standardize the research, development, utilization and transfer of China's genetically-engineered medicines as well as the management of production, sales and safety of such products, according to a motion tabled to the current annual session of the NPC.

The motion was tabled jointly by a group of NPC deputies headed by Prof. Kong Fanchao, president of the mathematics and physics college of Anhui University.

Kong said the genetic technologies are expected to provide a most effective approach to diagnosing diseases, developing new medicines and exploring new cures of diseases.

He said that Chinese scientists have developed gene-transferred test-tube cows, which carry human serum protein genes and can produce milk containing human serum protein. At present, at least 15 varieties of genetically-engineered medicines are on sale in China.

In the United States, however, more than 50 kinds of genetically-engineered medicines are on sale, and 350 are under examination and approval and 2,200 other are being developed.

He suggested that the state take an active attitude toward the R&D of genetically-engineered medicines while being cautious concerning the commercialization of such production.







In This Section
 

A law on the management of genetically-engineered medicines needs to be enacted to promote and systematically standardize the research, development, utilization and transfer of China's genetically-engineered medicines as well as the management of production, sales and safety of such products, according to a motion tabled to the current annual session of the NPC.

Advanced Search


 


 


Copyright by People's Daily Online, all rights reserved